






The incidence of heart failure dramatically increases 
with aging. An important feature of cardiac aging is an 
increase in susceptibility to stress, such as ischemia and 
hemodynamic overload [1]. The heart is an organ in 
which mitochondria are abundant and mitochondrial 
dysfunction caused by oxidative stress is believed to be 
an important cause of aging and failure. Mitochondrial 
permeability transition pore (mPTP) opening, a 
hallmark of mitochondrial dysfunction, causes release 
of  pro-apoptotic  factors  and  depletion  of  ATP,           
and eventually induces apoptosis and necrosis of 
cardiomyocytes depending upon the severity of ATP 
depletion.  Elucidating the molecular mechanism by 
which mPTP opening is regulated during aging would 
provide an important clue for developing modalities to 
reduce the incidence of heart failure in elderly patients.  
 
In a recent publication, Hafner et al showed that Sirt3 
plays an essential role in fighting against cardiac aging 
and increases the tolerance of the heart against 
hemodynamic overload [2]. Sirt3 belongs to the sirtuin 
family proteins, which deacetylate cellular proteins in 
an NAD+-dependent manner. Sirt3 is localized prim-
arily at mitochondria and deacetylates cyclophilin D, a 
key component of the mPTP, thereby inhibiting mPTP 
opening. This in turn reduces oxidative stress and 
eventually slows down cardiac aging.  
 
Cardiac hypertrophy is often accompanied by oxidative 
stress, which causes oxidation and dysfunction of 
mitochondrial proteins, leading to further increases in 
mitochondrial  oxidative stress through an amplification 
process called reactive oxygen species (ROS)-induced 
ROS   release.   Transition  from   hypertrophy  to  heart 
 
 


































failure is almost always accompanied by increased 
oxidative  stress  and  mitochondrial dysfunction, which 
trigger another vicious cycle consisting of oxidative 
stress, mitochondrial dysfunction and cardiac hyper-
trophy/dysfunction. This often makes it difficult to 
determine whether a given intervention acts primarily 
on cardiac hypertrophy, oxidative stress, or mito-
chondria to improve overall cardiac function, since all 
are affected concomitantly. In this regard, the fact that 
Sirt3 localized in mitochondria directly prevents mPTP 
opening by modulating cyclophilin D strongly suggests 
that Sirt3’s primary action is to suppress mPTP opening 
and consequent mitochondrial dysfunction, and that the 
suppression of cardiac hypertrophy could be secondary 
to the suppression of mitochondrial/cardiac dysfunction 
[2]. The fact that Sirt3 inhibits cardiac hypertrophy was 
also demonstrated by Sundaresan et al, where the 
authors proposed that Sirt3 deacetylates FoxO3 in the 
cytosol and induces nuclear translocation of FoxO3, 
which promotes transcription of anti-oxidants [3]. 
However, modulation of FoxO3 was demonstrated only 
in the presence of overexpression of Sirt3 and, thus, 
whether endogenous Sirt3 deacetylates FoxO3 in the 
cytosol remains to be shown. Whether or not Sirt3 has 
an additional direct effect upon cardiac hypertrophy 
independent of mPTP opening remains to be clarified. 
 
Judging from the fundamental involvement of mPTP 
opening in myocardial cell death and the development 
of heart disease, modulation of Sirt3 could be an 
important modality for medical treatment of heart 
failure.  Sinclair and colleagues have shown that the 
NAD+ biosynthetic enzyme Nampt plays an important 
role in maintaining NAD+ content in mitochondria, and 
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Sirt4 [4]. It would be interesting to test whether 
interventions upon Nampt achieve the same effect in the 
heart as those upon Sirt3. We have shown recently that 
cardiac specific overexpression of Nampt induces 
protection against myocardial ischemia, in part through 
activation of autophagy, another cellular mechanism 
implicated in aging and lifespan extension [5].  
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It remains to be shown how the activity of endogenous 
Sirt3 is regulated by aging in the heart. If the activity of 
Sirt3 goes down with aging, it could itself be a cause of 
aging, and this process might be reversed by either 
increasing mitochondrial NAD+ content (with dietary 
restriction or exercise) or stimulating expression of 
Sirt3 (for example by inhibiting angiotensin II type I 
receptors) [6]. However, judging from the fact that the 
effect of Sirt3 knockdown upon mPTP opening is more 
prominent in aging hearts than in young hearts [2], Sirt3 
may actually be activated as a compensatory mech-
anism in aging hearts, while aging is mediated by other 
mechanisms. If so, it remains to be tested to what extent 
supplementation of NAD+ and Sirt3 would achieve 
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Transgenic expression of catalase in mitochondria 
extends lifespan, retards cardiac aging, and confers 
stress resistance to the heart [7].  We have shown that 
genetic deletion of adenylyl cyclase type 5, a cyclic 
AMP producing enzyme expressed in the brain and the 
heart, induces both lifespan extension and stress 
resistance in the heart [8]. The study by Hafner showed 
that Sirt3, implicated in lifespan extension in humans 
[9], also inhibits aging and makes the heart resistant to 
oxidative stress and heart failure [2]. The hormesis 
hypothesis proposes the idea that the mechanisms of 
lifespan extension and accumulation of stress resistance 
are connected [10]. Thus, enhancing a known 
mechanism of lifespan extension may allow us to retard 
aging and to achieve stress resistance in the heart. If this 
is the case, it would be interesting to investigate 
whether the aforementioned mechanisms of lifespan 
extension converge at a common mechanism, such as 
modulation of mPTP, to mediate anti-aging and stress 
resistance in the heart. 
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